Thanks were. Yes, as far as phase III cancer trials go, this one will be fairly low risk/have a high probability of success. Also, the Taiwanese ministry of health have already indicated that, should the phase IIb results be repeated, they are keen to make the drug available in the shortest possible time. So the immediate market for PI88 is clear.
It is also reassuring to know that this Asian trial can be fully funded (unlike the AVX deal) from PGL's post buy-back cash reserves. This means no further capital raisings – at least not until after the phase III data is out.
You would also have to assume, that, if PI88 is well received in Asia, PGL should have little trouble finding a partner to eventually fund EU/US trials for both PI88 and the 500 series.
The sad irony is that what PGL management is doing now is precisely what the PSG and other sophisticated investors have been arguing for over the last 6 months. If management had listened to the wisdom of its sophisticated shareholders (many of which have more biotech experience than PGL's old BOD) 6 months ago, then PI88 Asian trials would already have begun, and PGL would now be $4mill richer (that's how much was wasted on AVX and related expenses to 3rd parties).
PGL Price at posting:
77.7¢ Sentiment: LT Buy Disclosure: Held
